Pittsburgh participants may never learn their own brain test results

People in a historically Black corner of Pittsburgh took memory tests, tracked their sleep and blood pressure, and shared stories of their past to help scientists unravel the risks of Alzheimer’s disease. The study was among broader research into why Black Americans are twice as likely as their white peers to develop Alzheimer’s, and the Trump administration abruptly halted it in its final stretch.

Researchers say the move wasted more than $8 million in taxpayer money already spent and dealt a blow to the trust of study participants who will not learn whether their brain tests showed signs of trouble. The project had been near completion in its fifth and final year.

“The community will look like, ‘Oh, they came in here, they took all our stuff, they checked us out. Now they’re gonna leave us hanging,’” said Roderick Blair, 70, who had taken part in the study for four years.

Trust in U.S. health institutions has long been strained in the Black community, stemming from long-standing racial health inequities, unequal access to care and bias within the medical system. The legacy of the Tuskegee study, which withheld treatment from Black men infected with syphilis in the 1930s, still casts a shadow.

The Pittsburgh study had overcome some of that mistrust. La’Vette Wagner, the study’s field coordinator, said work in the city’s Hill and Homewood communities got people talking about memory loss, dementia and Alzheimer’s and helped challenge misconceptions about the disease. Families who once dismissed memory loss as depression began asking about dementia, and people outside the study called her to ask whether relatives could join, she said.

More than half of Black Americans, or 55%, believe a significant loss of memory or cognitive ability is a natural part of aging rather than a disease, according to the Alzheimer’s Association. Blair described the uncertainty the research was meant to address: “You start forgetting things and you start to wonder, do you have Alzheimer’s? You wonder, do you have dementia?”

The study was stripped of funding last year by the National Institutes of Health on the grounds that it was “not science,” according to its researchers, despite a rigorous review and vetting from a community advisory board. “It wasn’t a Black study or a DEI study,” Wagner said. “It was something that was happening that was real.”

Similar terminations happened around the country. Negar Fani, a neuropsychologist at Emory University in Atlanta, was two years into a five-year, $2.9 million project on how daily experiences of racial discrimination affect the brain and body of Black Americans when the NIH terminated it in July. Fani is trying to find roughly $2.3 million to complete the study, and she and her team were left to explain the situation to participants who feel abandoned.

“It takes a lot to restore trust with the Black community, who has experienced so many different betrayals,” she said. Fani said her grant had been terminated for being “not scientific” and “subjective,” after the study had been approved and had enrolled 66 of the 220 people it needed. “It’s simply brain science research,” she said.

In Pittsburgh, study lead researcher Andrea Rosso is one of numerous scientists in a recently filed lawsuit against the NIH and its parent Department of Health and Human Services, one of a growing body of legal actions as the administration continues to hunt for and halt medical grants whose descriptions include the words “disparities,” “minority” and “racial.” Ann Cohen, a director of Pittsburgh’s Alzheimer’s Disease Research Center, is also part of that lawsuit after her separate, complementary study of Alzheimer’s risk was halted, following $5.2 million spent over three years. She faces an ethics question of her own: what to do with the blood samples collected from participants.

“You lose trust a hell of a lot faster than you build it,” Cohen said.

A spokesperson for HHS said: “Massive amounts of DEI grants have failed to translate into better health outcomes for minority populations. Following President Trump’s directives, NIH is shifting money into rigorous research that will help Americans — including minority populations — live longer, healthier lives.”

This year the NIH has awarded 2,000 fewer grants for multiyear studies, worth a total of $200 million, compared with 2025, according to an Association of American Medical Colleges report.

“It’s unprecedented. Many of the decisions are based on political biases and based on what politicians think is valuable rather than peer review processes, evidence-based decisions about where to invest our research dollars,” said Jill Rosenthal, director of public health policy at the Center for American Progress. “We’re wasting resources, we’re wasting the opportunity to identify cures for diseases,” she said.

Researchers in Pittsburgh say they are especially concerned that promises made to the community will go unfulfilled. The study, 15 years in the making, would have helped identify participants at higher risk for Alzheimer’s — and for the doctor’s visits and care that follow.

Wagner said the findings are “stuck on a shelf,” and that more than a decade of trust built with participants has been breached. Blair said reinstating that trust will be an uphill battle. “It’s going to take years to reestablish something that was moving pretty good,” he said.